Skip to main content
SpringerLink
Log in

Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

The molecular subgrouping of diffuse gliomas was recently found to stratify patients into prognostically distinct groups better than histological classification. Among several molecular parameters, the key molecules for the subtype diagnosis of diffuse gliomas are IDH mutation, 1p/19q co-deletion, and ATRX mutation; 1p/19q co-deletion is undetectable by immunohistochemistry, but is mutually exclusive with ATRX and p53 mutation in IDH mutant gliomas. Therefore, we applied ATRX and p53 immunohistochemistry instead of 1p/19q co-deletion analysis. The prognostic value of immunohistochemical diagnosis for Grade III gliomas was subsequently investigated. Then, the same immunohistochmical diagnostic approach was expanded for the evaluation of Grade II and IV diffuse glioma prognosis. The results indicate immunohistochemical analysis including IDH1/2, ATRX, p53, and Ki-67 index is valuable for the classification of diffuse gliomas, which is useful for the evaluation of prognosis, especially Grade III gliomas and lower-grade gliomas (i.e., Grade II and III).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146

    Article  CAS  PubMed  Google Scholar 

  2. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693

    Article  CAS  PubMed  Google Scholar 

  3. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P (2014) International Society Of Neuropathology-Haarlem. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435

    Article  PubMed  Google Scholar 

  4. Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563

    Article  CAS  PubMed  Google Scholar 

  5. Tanboon J, Williams EA, Louis DN (2015) The Diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol 75:4–18. doi:10.1093/jnen/nlv009

    Article  Google Scholar 

  6. Takano S, Kato Y, Yamamoto T, Liu X, Ishikawa E, Kaneko MK, Ogasawara S, Matsuda M, Noguchi M, Matsumura A (2015) Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas. Brain Tumor Pathol 32:169–175

    Article  CAS  PubMed  Google Scholar 

  7. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451

    Article  CAS  PubMed  Google Scholar 

  9. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    Article  CAS  PubMed  Google Scholar 

  10. Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, Tonn JC, Kretzschmar HA, Kreth FW (2009) Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol 68:1219–1228

    Article  PubMed  Google Scholar 

  11. Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K (2015) Revisiting TP53 Mutations and Immunohistochemistry—a comparative study in 157 diffuse gliomas. Brain Pathol 25:256–265

    Article  CAS  PubMed  Google Scholar 

  12. Kaneko MK, Ogasawara S, Kato Y (2013) Establishment of a multi-specific monoclonal antibody MsMab-1 recognized both IDH1 and IDH2 mutations. Tohoku J Exp Med 230:103–109

    Article  CAS  Google Scholar 

  13. Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A (2012) Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108:361–373

    Article  CAS  PubMed  Google Scholar 

  14. Haberler C, Wöhrer A (2014) Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. Clin Neuropathol 33(2):108–111

    Article  PubMed  PubMed Central  Google Scholar 

  15. Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, Schoppmann SF, Tchorbanov A, Streubel B, Tuettenberg J, Guentchev M (2014) Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer 120:2440–2447

    Article  CAS  PubMed  Google Scholar 

  16. Mashiko R, Takano S, Ishikawa E, Yamamoto T, Nakai K, Matsumura A (2011) Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol 102:43–50

    Article  CAS  PubMed  Google Scholar 

  17. Cancer Genome Atlas Research Network, Brat DJ et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498

  18. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468

    Article  CAS  PubMed  Google Scholar 

  20. Ichimura K, Narita Y, Hawkins CE (2015) Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathol 129:789–808

    Article  CAS  PubMed  Google Scholar 

  21. Shao LW, Pan Y, Qi XL, Li YX, Ma XL, Yi WN, Zhang J, Zhong YF, Chang Q (2016) ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients. Histol Histopathol 31:103–114

    PubMed  Google Scholar 

  22. Hewer E, Vajtai I, Dettmer MS, Berezowska S, Vassella E (2016) Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas. Histopathology 68:272–278

    Article  PubMed  Google Scholar 

  23. Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC (2009) Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study. Neuropathol Appl Neurobiol 35:367–379

    Article  CAS  PubMed  Google Scholar 

  24. Wakimoto H, Aoyagi M, Nakayama T et al (1996) Prognostic significance of Ki-67 labelling indices obtained using MIB1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77:373–380

    Article  CAS  PubMed  Google Scholar 

  25. Cai J, Yang P, Zhang C, Zhang W, Liu Y, Bao Z, Liu X, Du W, Wang H, Jiang T, Jiang C (2014) ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples. Oncotarget 5:2551–2561

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T (2012) Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One 7:e30339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, Yan W, Yo Y (2015) IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget 6:30232–30238

    PubMed  PubMed Central  Google Scholar 

  28. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129:585–596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Borodovsky A, Meeker AK, Kirkness EF, Zhao Q, Eberhart CG, Gallia GL, Riggins GJ (2015) A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. J Neurooncol 121:479–487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. England B, Huang T, Karsy M (2013) Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34:2063–2074

    Article  CAS  PubMed  Google Scholar 

  31. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C (2013) IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol 9:1923–1935

    Article  CAS  PubMed  Google Scholar 

  32. Walerych D, Lisek K, Del Sal G (2015) Mutant p53: one, no one, and one hundred thousand. Front Oncol 5:289

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Yoshiko Tsukada and Makiko Miyakawa for their excellent technical assistance. This work was supported in part by Grants-in-Aid for Scientific Research (to S. T., No. 15H04947) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and by the Japan Brain Foundation (to S. T.) and the Japanese Foundation for Multidisciplinary Treatment of Cancer (to S. T.).

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Shingo Takano, Eiichi Ishikawa, Noriaki Sakamoto, Masahide Matsuda, Hiroyoshi Akutsu, Tetsuya Yamamoto & Akira Matsumura

  2. Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Noriaki Sakamoto & Masayuki Noguchi

  3. Department of Regional Innovation, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan

    Yukinari Kato

Authors
  1. Shingo Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiichi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noriaki Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahide Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyoshi Akutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masayuki Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yukinari Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsuya Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shingo Takano.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takano, S., Ishikawa, E., Sakamoto, N. et al. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol 33, 107–116 (2016). https://doi.org/10.1007/s10014-016-0260-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-016-0260-x

Keywords

Search

Navigation